1Gary L, Davis MD. Current treatment for chronic hepatitis C. Rev Gas Dis, 2002, 1: 59-72. 被引量：1
2Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of virual hepatitis C: effects of dose and duration. Hepatology, 1996, 24: 778-789. 被引量：1
3Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a(40KD) (Pegasys) for the treatment of hepatitis C.Adevanced Drug Delivery Reviews, 2002, 54: 571-586. 被引量：1
4Reddy KR, Wright TL, Pockros PJ, et al. Effcacy and safety of peginterferon alfa-2a compared with interferon alfa-2a in noncirrhotic patients with hepatitis C. Hepatology, 2001, 33: 433-438. 被引量：1
5Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997, 26:473-477. 被引量：1
6Bisceglie AMD, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology, 2002, 35: 224-231. 被引量：1
7Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled studies. Gastroenterology, 1999, 117:403-413. 被引量：1
8Fried MW, Shiffman ML, Reddy KR, et al. Pegylated interferon alfa-2a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomized, acitively controlled, multicenter study. Gastroenterology, 2001, 120: A55. 被引量：1
9Sulkowski MS, Reindollar R, Thomas DL, et al. Combination therapy with peginterferon alfa-2a (Pegasys) and ribavirin in ther treatment of patients with chronic hepatitis C: a phase II open-label study.Bio Drugs, 2002, 16: 105-109. 被引量：1
10McHutchison JG, Poynard I. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis, 1999, 19: 57-65. 被引量：1
